Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication’s issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

<table>
<thead>
<tr>
<th>Bone Marrow Transplant</th>
<th>Gynecologic</th>
<th>Immunotherapy</th>
<th>Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Head &amp; Neck</td>
<td>Melanoma/Skin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hematology</td>
<td>Neuro-Oncology</td>
<td>Thoracic</td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bone Marrow Clinical Trials**

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**BONE MARROW TRANSPLANT**

**STUDY 2015-115**

Phase II

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

**STUDY NEW 2018-145**

Phase III

Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)

**STUDY NEW 2019-024**

Phase I/II
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

STUDY 2019-011
Phase I/II
A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

STUDY 2018-084
Phase I/II
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

STUDY BMTCTN1506
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2018-128
Phase II
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

STUDY 2017-081
Phase III
Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

STUDY 2014-103
Phase I/II
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

STUDY 2016-049
Phase I/II
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

STUDY 2011-086
NA
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

IMMUNOTHERAPY
STUDY 2018-008
Phase III
A Phase 3, Randomized, Open-Label Study of Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Breast Clinical Trials
For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.
ADJUVANT STUDY NRG-BR003
Phase III
A Randomized Phase III Trial of Adjunct Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

STUDY A011502
Phase III
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjunct Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT HORMONAL STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT RADIATION STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

NEOADJUVANT STUDY RTOG1304
Phase III
NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

STUDY S1418
Phase III
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjunct Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

STUDY EA1131
Phase III
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neo-adjuvant Chemotherapy

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADVANCED (STAGE IV) CHEMOTHERAPY STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2018-009</td>
<td>Phase II</td>
<td>A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2018-054</td>
<td>Phase I</td>
<td>A Phase 1a/1b Study of FPA150, and Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td>OTHERS STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY S1501</td>
<td>Phase III</td>
<td>Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III</td>
</tr>
<tr>
<td>STUDY 2017-073</td>
<td>Phase II</td>
<td>The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with Early Stage Breast Cancer</td>
</tr>
<tr>
<td>STUDY A011401</td>
<td>Phase III</td>
<td>Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2016-116</td>
<td>Phase II</td>
<td>A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-029</td>
<td>Phase I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
</tr>
<tr>
<td>STUDY 2017-018</td>
<td>Phase I</td>
<td>A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer</td>
</tr>
<tr>
<td>Study Code</td>
<td>Phase</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>STUDY 2018-006</td>
<td>NA</td>
<td>Educational Interventions to Promote Tobacco Cessation Among Women Seeking Mammography Screening</td>
</tr>
<tr>
<td>STUDY 2018-062</td>
<td>NA</td>
<td>Reducing Metabolic Syndrome and Unmet needs Among Rural Breast Cancer Survivors During the Survivorship Transition</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
</tbody>
</table>

**Gastrointestinal Clinical Trials**

For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**Esophagus**

**Metastatic**

<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
</tbody>
</table>

**Gastric and Gastroesophageal Junction**

**Metastatic**

<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-210</td>
<td>Phase I/II</td>
<td>An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
</tr>
<tr>
<td>STUDY 2017-150</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma</td>
</tr>
<tr>
<td>STUDY 2017-149</td>
<td>Phase I</td>
<td>A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer</td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>Study 2018-088</td>
<td>Phase III</td>
<td>A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2 Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</td>
</tr>
<tr>
<td>Study 2017-029</td>
<td>Phase I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
</tr>
<tr>
<td>Study 2016-003</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</td>
</tr>
<tr>
<td>Study 2016-037</td>
<td>Phase I</td>
<td>A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>Study 2018-047</td>
<td>Phase II</td>
<td>A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Unresectable Gastic or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression</td>
</tr>
<tr>
<td>Study 2018-048</td>
<td>Phase III</td>
<td>PANova-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFIELDS, 150kHz) Concomitant with Gemcitabine and nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma</td>
</tr>
<tr>
<td>Study 2018-090</td>
<td>Phase III</td>
<td>A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus...</td>
</tr>
<tr>
<td>Study</td>
<td>Phase</td>
<td>Title</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>HCC</td>
<td>Adjuvant</td>
<td>STUDY NEW 2019-048</td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>BILIARY/GALL BLADDER</td>
<td>Metastatic</td>
<td>STUDY 2017-101</td>
</tr>
<tr>
<td></td>
<td>Phase I/II</td>
<td>A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STUDY 2017-064</td>
</tr>
<tr>
<td></td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STUDY S1815</td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STUDY 2014-081</td>
</tr>
<tr>
<td></td>
<td>Phase II</td>
<td>A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy</td>
</tr>
<tr>
<td>COLON</td>
<td>Adjuvant</td>
<td>STUDY A021502</td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair</td>
</tr>
<tr>
<td>Metastatic (Includes Rectal)</td>
<td>1st Line</td>
<td>STUDY NRG-GI004</td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer</td>
</tr>
<tr>
<td>Metastatic (Includes Rectal)</td>
<td>2nd Line</td>
<td>STUDY 2016-055</td>
</tr>
<tr>
<td></td>
<td>Phase I</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Phase</td>
<td>Title</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>STUDY 2016-185</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</td>
</tr>
<tr>
<td>STUDY 2018-021</td>
<td>Phase II</td>
<td>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</td>
</tr>
<tr>
<td>STUDY 2017-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizmab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-129</td>
<td>NA</td>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasability and Utilization of an Application-based Question Prompt List</td>
</tr>
<tr>
<td>STUDY EA2165</td>
<td>Phase II</td>
<td>A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</td>
</tr>
<tr>
<td>STUDY EA2165</td>
<td>Phase II</td>
<td>A Randomized PHase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</td>
</tr>
<tr>
<td>STUDY 2018-122</td>
<td>Phase II</td>
<td>A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal</td>
</tr>
</tbody>
</table>

**NEUROENDOCRINE TUMORS AND CARCINOID**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Pilot</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-144</td>
<td>Pilot</td>
</tr>
</tbody>
</table>
Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using alpha-[11C]methyl-L-tryptophan (AMT)-PET

IMAGING STUDIES

Metastatic
STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2006-127
NA
Use of [F-18] FLT for Imaging with Positron Emission Tomography (PET)

OTHER
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Genitourinary Clinical Trials

For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

RENAL
STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-024
Phase II
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

STUDY S1500
Phase II
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

STUDY 2017-082
Phase I/II
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2017-111**  
**Phase I**  
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

**STUDY 2016-211**  
**Phase II**  
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

**STUDY 2017-029**  
**Phase I**  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

**STUDY 2016-157**  
**Phase I**  
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

**STUDY 2017-064**  
**Phase I/II**  
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

**STUDY 2016-055**  
**Phase I**  
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2018-098**  
**Phase I/II**  
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

**PROSTATE**  
**STUDY 2013-108**  
NA  
Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer

**STUDY 2016-157**  
**Phase I**  
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

**STUDY NEW 2019-029**  
**Phase III**  
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy(KEYLYNK-010)

**STUDY NEW 2018-170**  
NA  
Genetic Counseling Processes and Outcomes Among Males with Prostate Cancer (ProGen)

**STUDY NEW 2019-027**  
**Phase II**  
IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations
STUDY NEW 2019-035
Phase II
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

STUDY NEW 2019-030
Phase III
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

STUDY NRG-GU002
Phase II/III
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

STUDY 2018-124
Phase I/II
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY S1802
Phase III
Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.

STUDY 2018-173
Phase III
The MAP TRIAL: Phase III Study of Muscadine Plus (MPX) in Men with Prostate Cancer: A Randomized Double-Blind, Placebo-Controlled Study of the Effects of MPX Capsules on Rising Prostate-Specific Antigen Levels in Alanine/Alanine SOD2 Genotype Men Following Initial Therapy for Prostate Cancer

STUDY 2017-126
Phase II
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

STUDY EA8153
Phase II
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: Phase II the CHAARTED2 Trial

STUDY NRG-GU005
Phase III
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

STUDY 2015-135
Phase II
Phase II Trial of Immune Checkpoint Inhibitor with Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.

STUDY 2017-092
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2015-167
Phase II
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-046</td>
<td>Phase I</td>
<td>A Phase IB Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Androgen Deprivation Therapy and Other Agents in Subjects with Castrate Resistant Prostate Cancer (CRPC)</td>
</tr>
<tr>
<td>STUDY 2015-029</td>
<td>Phase II</td>
<td>Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-156</td>
<td>Phase II</td>
<td>A Phase II Open-Label, a Multisite Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY 2017-129</td>
<td>NA</td>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List</td>
</tr>
<tr>
<td>STUDY 2018-017</td>
<td>Phase II</td>
<td>A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Doxetaxel, or Enzalutamide in Men with Castration Resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint Pathway and NivolumAb Clinical Trial Evaluation 9KD)</td>
</tr>
<tr>
<td>STUDY 2018-092</td>
<td>Phase III</td>
<td>An international, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of Lu-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-resistant Prostate Cancer (mCRPC)</td>
</tr>
<tr>
<td>BLADDER</td>
<td>STUDY 2016-055</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2017-070</td>
<td>Phase II</td>
<td>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin(BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2019-019</td>
<td>Phase II</td>
<td>A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy</td>
</tr>
</tbody>
</table>
STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2016-195
Phase II
Phase II Trial of Concurrent Nivolumab in UroThelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]

STUDY 2018-110
Phase II
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2017-092
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2018-165
Phase III
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)

STUDY 2016-175
Phase II
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-044
Phase II
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2017-101
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities
STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2018-023
Phase I/II
An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY 1163877) in Combination with Atezolizumab as First-line Treatment in Cisplatin-Ineligible Patients with FGFR-positive locally advanced or metastatic urothelial carcinoma

STUDY 2018-098
Phase I
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

OTHER
STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PE Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

Gynecologic Clinical Trials
For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

CERVIX
STUDY 2017-010
Phase II
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-103
Phase III
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

OVARY
STUDY GOG-3020
Phase III
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Study Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2018-043</td>
<td>Phase III</td>
<td>A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</td>
</tr>
<tr>
<td>STUDY GOG-3018</td>
<td>Phase III</td>
<td>The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer</td>
</tr>
<tr>
<td>STUDY 2018-159</td>
<td>Phase II</td>
<td>Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen</td>
</tr>
<tr>
<td>STUDY NEW NRG-GY014</td>
<td>Phase II</td>
<td>A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma</td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-054</td>
<td>Phase I</td>
<td>A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Solid Advanced Tumors</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-029</td>
<td>Phase I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy of BI 754091 In Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td>UTERUS</td>
<td>STUDY 2017-064</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>OTHER</td>
<td>STUDY NEW NRG-GY014</td>
<td>A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma</td>
</tr>
</tbody>
</table>
STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

RETURN TO TOP

Head & Neck Clinical Trials

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

STAGES I/II/III
STUDY 2016-093
Phase I/II
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY EA3132
Phase II
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

STUDY NEW 2018-117
Phase II
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).

STUDY NEW 2018-168
Phase III
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy

STUDY EA3163
Phase II
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

STUDY RTOG1008
Phase II/III
A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

STUDY 2016-212
Phase II
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-107
Phase III
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942(Dusquetide) for the Treatment of Oral
Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

**STUDY 2017-069**  
Phase I/II  
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2016-017**  
Phase I/II  
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

**STUDY 2018-098**  
Phase I/II  
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

**OTHER**  
**STUDY 2017-064**  
Phase I/II  
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

**STUDY 2016-055**  
Phase I  
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2018-171**  
Phase II  
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

**STUDY 2017-101**  
Phase I/II  
A Dose-Finding Phase I Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

**STUDY 2016-037**  
Phase 1  
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Hematology Clinical Trials

For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**MULTIPLE MYELOMA**  
**STUDY 2012-122**  
Phase I/II
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-120</td>
<td>Phase I</td>
<td>Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2016-062</td>
<td>Phase I/II</td>
<td>Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2017-136</td>
<td>Pilot</td>
<td>Pilot Study of Dabrafenib and/or Trametinib in Patients with Relapsed and/or Refractory Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2017-151</td>
<td>Phase IV</td>
<td>Phase 1/2 Trial of Idasanutlin in Combination with Ixazomib and Dexamethasone in Patients with 17p Deleted, Relapsed Phase I/II Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2018-014</td>
<td>Phase I</td>
<td>A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2018-028</td>
<td>Phase II</td>
<td>A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens</td>
</tr>
<tr>
<td>STUDY 2016-086</td>
<td>Phase I</td>
<td>A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2018-026</td>
<td>Phase II</td>
<td>A Phase II Study of CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma</td>
</tr>
<tr>
<td>STUDY 2018-176</td>
<td>Phase I/II</td>
<td>MyDRUG: Myeloma-Developing Regimens Using Genomics (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination with a Backbone Regimen)</td>
</tr>
<tr>
<td>STUDY NEW 2019-054</td>
<td>Phase II</td>
<td>A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment</td>
</tr>
<tr>
<td>STUDY 2014-090</td>
<td>Phase I</td>
<td>A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.</td>
</tr>
<tr>
<td>STUDY 2019-006</td>
<td>Phase I/II</td>
<td>Study of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.</td>
</tr>
</tbody>
</table>
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

**AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE**

**STUDY 2016-200**
Phase II
A Randomized Phase 2 Trial of Revlimid/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide followed by Revlimid/ Dexamethasone/Elotuzumab Maintenance as Second-line Therapy for Patients with Relapsed AL Amyloidosis

**STUDY S1702**
Phase II
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated Phase II AL Amyloidosis

**STUDY 2017-067**
Phase III
Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

**STUDY 2016-060**
Phase I
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123x CD3 DouBody in Subjects with Relapsed or Refractory AML

**LEUKEMIA**

**Acute Lymphoblastic Leukemia (ALL)**

**STUDY E1910**
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

**Acute Myeloid Leukemia (AML)**

**STUDY BMTCTN1506**
Phase III
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABLnegative B lineage Acute Lymphoblastic Leukemia in Adults

**STUDY 2018-027**
Phase II/II
A Phase II/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy

**STUDY 2017-119**
Phase III
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects < or = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

**STUDY 2015-093**
Phase II
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy

**STUDY 2017-120**
Phase III
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-035</td>
<td>Phase I</td>
<td>A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation</td>
</tr>
<tr>
<td>STUDY 2016-033</td>
<td>Phase I/II</td>
<td>An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>STUDY 2015-128</td>
<td>Phase II</td>
<td>A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses</td>
</tr>
<tr>
<td>STUDY 2014-132</td>
<td>Phase III</td>
<td>A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study</td>
</tr>
<tr>
<td>STUDY 2015-128</td>
<td>Phase II</td>
<td>A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses</td>
</tr>
<tr>
<td>STUDY 2013-047</td>
<td>Phase I</td>
<td>A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas</td>
</tr>
<tr>
<td>STUDY 2017-100</td>
<td>Phase III</td>
<td>Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivolumAb clinical Trial Evaluation 812)</td>
</tr>
<tr>
<td>STUDY 2017-132</td>
<td>Phase II</td>
<td>An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)</td>
</tr>
<tr>
<td>STUDY 2018-094</td>
<td>Phase I/II</td>
<td>An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>STUDY 2015-150</td>
<td>Phase II</td>
<td>A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas</td>
</tr>
<tr>
<td>Study Number</td>
<td>Phase</td>
<td>Title</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>STUDY 2018-008</td>
<td>Phase III</td>
<td>A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>STUDY 2014-132</td>
<td>Phase III</td>
<td>A Phase 3b, Multicenter, Open-Label, PCI-32765 (Ibrutinib) Long-term Extension Study</td>
</tr>
<tr>
<td>STUDY 2016-210</td>
<td>Phase I/II</td>
<td>A Phase Ia/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma</td>
</tr>
<tr>
<td>STUDY 2016-056</td>
<td>Phase II</td>
<td>A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (&lt;10%) Mature T Cell Lymphoma (TCL)</td>
</tr>
<tr>
<td>STUDY 2016-003</td>
<td>Phase I/II</td>
<td>A Phase I, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY NEW 2018-119</td>
<td>Phase I/II</td>
<td>A Phase I, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naive Patients Not Eligible for Intensive Induction Therapy</td>
</tr>
</tbody>
</table>
OTHER
STUDY 2013-113
Phase II
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

Immunotherapy Clinical Trials
For more information on Immunotherapy Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

IMMUNOTHERAPY
STUDY 2018-015
Phase I/II
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

Melanoma/Skin Clinical Trials
For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVANT
STUDY 2018-095
Phase III
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

ADVANCED
STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY NEW EA6134
Phase III
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

OTHER
STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-128
Phase III
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Neuro-Oncology Clinical Trials
There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.
## Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

**ALL SOLID TUMORS**

**STUDY 2017-111**
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

**STUDY 2017-122**
Phase I
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2018-019**
Phase I
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

**STUDY 2018-079**
Phase I
A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients with FGFR-positive, Locally Advanced or Metastatic Solid Tumors

**STUDY 2018-156**
Phase I
A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

**STUDY 2017-084**
Phase I
Phase 1b Multi-Indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

**STUDY 2016-170**
Phase I/II
A Phase I/IIa, Open-Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy

**STUDY 2018-104**
Phase I/II
A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies

**STUDY 2016-210**
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2018-034**
Phase I
### A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2016-185**
- **Phase I/II**
- A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced ColoRectal Cancer

### A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2017-052**
- **Phase I/II**
- A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

### A Phase 1 Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

**STUDY 2018-154**
- **Phase I**
- A Phase 1/1b Open-Label Multi-Center to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Metastatic or Locally-Advanced Solid Tumor or Lymphoma

### Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy

**STUDY 2018-158**
- **Phase I/II**
- First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

### A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

**STUDY 2018-037**
- **Phase I**
- A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

### A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

**STUDY 2018-066**
- **Phase I**
- A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects with Selected Advanced Solid Tumors

### A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

**STUDY 2018-035**
- **Phase I**
- A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

### A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

**STUDY 2018-054**
- **Phase I**
- A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

### A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

**STUDY 2017-101**
- **Phase I/II**
- A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

### An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas

**STUDY NEW 2018-157**
- **Phase I**
- An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas
STUDY 2017-086
Phase I/II
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

STUDY 2018-100
Phase I
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies

STUDY NEW 2018-109
Phase I/II
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

TUMOR SPECIFIC
STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY NEW 2018-157
Phase I
An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-120
Phase I/II
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-166
Phase I/II
A Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-018
Phase I
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

GENOMIC TESTING SPECIFIC
STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-079
Phase I
A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients with FGFR-positive, Locally Advanced or Metastatic Solid Tumors

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

RETURN TO TOP

Sarcoma Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

RETURN TO TOP

Thoracic Clinical Trials
For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**ADJUVENT**
**STUDY 2018-142**
Phase III
A Phase III, Double-blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or SELECT IIIB Non-Small Cell Lung Cancer

**MAINTENANCE**
**STUDY NRG-LU002**
Phase II/III

**STUDY NRG-LU004**
Phase I
Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

**STAGE I/II**
**STUDY 2016-110**
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

**STUDY NEW 2019-018**
Phase I/II
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

**STUDY 2018-098**
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted in Adult Patients with Selected Solid Tumors

**STAGE III A/B**
**STUDY 2016-110**
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

**STUDY 2017-152**
Phase II
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

**STUDY 2018-120**
Phase I/II
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

**STUDY S1400**
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
STUDY NEW 2019-034
Phase III
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

STUDY NEW 2019-036
Phase III
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer

STUDY 2018-065
Phase II
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY S1900A
Phase II
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

STUDY 2018-111
Phase III
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

STUDY 2018-060
Phase II
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STAGE IV
ALK
STUDY 2018-080
Phase II
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

EGFR
STUDY 2017-145
Phase II
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Other Genetic Marker
STUDY S1400
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase Type</th>
<th>Study Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-145</td>
<td>Phase II</td>
<td>A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)</td>
</tr>
<tr>
<td>STUDY S1900A</td>
<td>Phase II</td>
<td>A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)</td>
</tr>
<tr>
<td>STUDY 2018-065</td>
<td>Phase II</td>
<td>A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-120</td>
<td>Phase I/II</td>
<td>An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma</td>
</tr>
<tr>
<td>STUDY 2017-111</td>
<td>Phase I</td>
<td>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-017</td>
<td>Phase I/II</td>
<td>A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2014-002</td>
<td>Phase II</td>
<td>A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-060</td>
<td>Phase II</td>
<td>A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>Phase I/II</td>
<td>A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens</td>
</tr>
</tbody>
</table>
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2018-053
Phase III
METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

RECURRENT
ALK
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Other Genetic Marker
STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2018-065
Phase II
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

SCLC EXTENSIVE
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

MESOTHELIOMA
STUDY 2018-105
Phase II
Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

OTHER
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2018-081
Phase I
A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations

STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Iplilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours